Compositions and methods related to anti-CD19 antibody drug conjugates
US11827703B2 · kind B2 · utility
1Cited by
15References
41Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | May 9, 2019 |
| Grant date | Nov 28, 2023 |
| Priority date | — |
| Expiry date | Feb 28, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/622
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to antibody-drug conjugates (ADCs) wherein one or more active agents are conjugated to an anti-CD19 antibody through a linker. The linker may comprise a unit that covalently links active agents to the antibody. The disclosure further relates to monoclonal antibodies and antigen binding fragments, variants, multimeric versions, or bispecifics thereof that specifically bind CD19, as well as methods of making and using these anti-CD19 antibodies and antigen-binding fragments thereof in a variety of therapeutic, diagnostic and prophylactic indications.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.